Research Article
Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
Table 3
Summary of base case results.
| Treatment scenario | Cost (USD) | Unadjusted life years | QALY | ICER |
| 1 | BSC, all | 29614 | 0.48 | 0.21 | –– | 2 | PAC, all | 40108 | 0.88 | 0.41 | 53705 | 4 | PEM all | 108408 | 0.98 | 0.47 | Dominated | 5 | PDL1 + (CPS > 1%): PEM PDL1-: PAC | 77359 | 0.98 | 0.47 | Dominated | 3 | RAM/PAC all | 128775 | 1.05 | 0.49 | Dominated | 6 | MSI-H: PEM MSS: PAC | 72442 | 1.05 | 0.51 | 325611 | 7 | PDL1 + (CPS > 1%): PEM PDL1-: RAM/PAC | 130560 | 1.09 | 0.52 | Weakly dominated | 8 | MSI-H: PEM MSS: RAM/PAC | 152242 | 1.2 | 0.58 | 1074620 |
|
|